Clinical Trials
399
Active:20
Completed:193
Trial Phases
6 Phases
Early Phase 1:12
Phase 1:130
Phase 2:124
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (387 trials with phase data)• Click on a phase to view related trials
Phase 1
130 (33.6%)Phase 2
124 (32.0%)Not Applicable
114 (29.5%)Early Phase 1
12 (3.1%)Phase 3
5 (1.3%)Phase 4
2 (0.5%)A Food Security Intervention for the Prevention of Cancer in Low-income Families
Not Applicable
Not yet recruiting
- Conditions
- Obesity-Related Malignant Neoplasm
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT07039630
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
- Interventions
- Biological: Anti-CFH Monoclonal Antibody GT103Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT07017829
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Phase 2
Not yet recruiting
- Conditions
- Cancer-Associated AnorexiaHead and Neck Squamous Cell CarcinomaNeck Squamous Cell Carcinoma of Unknown Primary
- Interventions
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 66
- Registration Number
- NCT06995508
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Alpha-Stim AID® Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers
Not Applicable
Not yet recruiting
- Conditions
- Psychiatric Disorder
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06977503
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaRecurrent Hepatocellular CarcinomaRefractory Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- Biological: Anti-GPC3-CAR Autologous T LymphocytesProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06968195
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 80
- Next
News
No news found